{"id":201108,"date":"2026-08-13T11:48:19","date_gmt":"2026-08-13T06:18:19","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=201108"},"modified":"2026-08-13T11:48:22","modified_gmt":"2026-08-13T06:18:22","slug":"cipla-vs-lupin","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/cipla-vs-lupin\/","title":{"rendered":"Cipla vs Lupin: Share Price, PE and ROE Compared"},"content":{"rendered":"
<\/div>\n

Cipla MCap approx Rs 1,00,000-1,15,000 Cr. Lupin MCap approx Rs 85,000-1,00,000 Cr. Both are India top-5 listed pharma companies with US and domestic businesses.<\/em><\/p>\n

\n

Quick Answer<\/strong><\/p>\n

Cipla and Lupin are two of India’s top five listed pharmaceutical companies. Both are large-caps with significant US generics and domestic branded formulations businesses. Cipla has historically had a strong branded India business; Lupin has a large US portfolio focused on complex generics and inhalers. Both trade at premium valuations reflecting pharma sector growth expectations.<\/p>\n<\/div>\n

The Cipla vs Lupin question comes up often among investors who follow the Large pharma companies space in India. Cipla MCap approx Rs 1,00,000-1,15,000 Cr. Lupin MCap approx Rs 85,000-1,00,000 Cr. This article goes through what each company does, their latest financial performance, and the key numbers that matter for anyone evaluating Cipla vs Lupin as a research exercise.<\/p>\n

All data cited here is sourced from publicly available company filings. Note: Data is approximate. Verify the latest prices and fundamentals on NSE or BSE before acting on any information.<\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n